Bevacizumab plus Capecitabine

DRUG2 trials

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University, Nanfang Hospital, Southern Medical University

Conditions

Colorectal CancerMetastatic Colorectal Cancer

Phase 2

Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityColorectal Cancer

Start: 2021-03-01End: 2023-02-01Target: 112Updated: 2022-07-26

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Nanfang Hospital, Southern Medical UniversityMetastatic Colorectal Cancer

Start: 2023-01-31End: 2025-12-31Target: 40Updated: 2023-01-06

Related Papers

Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.

Journal of Clinical Oncology2026-05-28

Efficacy and safety of fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.

Journal of Clinical Oncology2025-01-27